Skip to main content
Equibles
NDRA logo

NDRA · ENDRA Life Sciences Inc. · Metrics

Track NDRA — free

Use NDRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NDRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.06 +0.18 (+3.06%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, management believes that without the closing of the Merger, given our current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about our ability to continue as a going concern after the date that is one year from the date that these financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$9.06M
Shares
1.50M
Volume · Oct 2 39.79K Avg daily vol (3M) 36.4K

NDRA metrics

52 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.06
Market cap
$9.06M

Price action

20 metrics
Price change (1W)
+0.3%
Price change (30D)
+0.2%
Price change (3M)
+28.4%
Price change (6M)
+29.2%
Price change (YTD)
+33.8%
Price change (1Y)
+4.8%
Trailing year
Price change (5Y)
—
52-week high
$8.12
52-week low
$3.26
Change from 52-week high
-25.4%
Change from 52-week low
+85.9%
Annualized volatility
110.8%
Annualized volatility (3M)
95.8%
Beta
1.4
RSI (14D)
56.1
Price vs SMA 50
+16.7%
Price vs SMA 200
+27.0%
Avg volume (3M)
36,401
Relative volume
1.1
Average dollar volume
$197,510

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
1.50M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.4
reciprocal yield 69.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-65.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-03-31

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$6.65M
Net income (TTM)
−$5.92M
Trailing 12 months
Diluted EPS (TTM)
$-6.39
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.92

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+245.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-93.8%
Return on assets
-74.5%
Debt / equity
—
Current ratio
7.1
EBITDA (TTM)
−$6.61M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.74M
Total assets
$7.94M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.82M
Capital expenditures (TTM)
$18,670
R&D (TTM)
$1.95M
SG&A (TTM)
—
Stock compensation (TTM)
$1.32M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
10
13F filer change QoQ
+2
Institutional ownership
10.2%

Short interest

3 metrics
Short interest
2.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
47 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1681682 CUSIP 29273B500 Visit website Investor relations